HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of ocular scarring post glaucoma filtration surgery using the inflammatory cell and platelet binding modulator saratin in a rabbit model.

AbstractCLINICAL RELEVANCE:
Late complications can occur with use of current antimetabolites to prevent scarring following glaucoma filtration surgery (GFS). Safer, more targeted, anti-fibrosis agents are sought.
OBJECTIVES:
The protein saratin has been shown to exhibit anti-fibrotic and anti-thrombotic properties in response to injury, but had not been used for glaucoma surgery. The goal of this study was to compare the efficacy of saratin with that of the widely accepted mitomycin-C (MMC) in prolonging bleb survival following GFS in the rabbit model. Two saratin delivery routes were compared; a single intraoperative topical application versus a combination of intraoperative topical application with two additional postoperative injections.
METHODS:
Twenty-four New Zealand White rabbits underwent GFS and received either intraoperative topical saratin, intraoperative topical saratin plus two injections on post-operative days 4 and 8, balanced saline solution (BSS), or MMC. The bleb tissues and their elevation durations were compared based on clinical and histological findings.
RESULTS:
Rabbits receiving topical+injections of saratin had a mean bleb survival of 33.6±8.5 days, significantly higher than the negative BSS controls, which averaged 17.4±6.0 days (pā€Š=ā€Š0.018). No improvement over BSS was seen for rabbits receiving topical saratin only (15.5±4.8 days, pā€Š=ā€Š0.749). Rabbits receiving saratin did not develop bleb avascularity and thinning associated with MMC treatment and there were no apparent clinical signs of toxicity.
CONCLUSIONS:
Treatment with a single intraoperative topical application plus two additional postoperative injections significantly prolonged bleb elevation comparable to MMC, but without toxicity; however, topical application alone was ineffective.
AuthorsJeff Min, Zachary L Lukowski, Monica A Levine, Craig A Meyers, Ashley R Beattie, Gregory S Schultz, Don A Samuelson, Mark B Sherwood
JournalPloS one (PLoS One) Vol. 7 Issue 4 Pg. e35627 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID22558182 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Salivary Proteins and Peptides
  • saratin
  • Mitomycin
Topics
  • Administration, Topical
  • Animals
  • Blood Platelets (drug effects)
  • Cicatrix (etiology, prevention & control)
  • Disease Models, Animal
  • Eye (drug effects, pathology)
  • Fibrosis (etiology, prevention & control)
  • Filtering Surgery (adverse effects)
  • Glaucoma (pathology, surgery)
  • Humans
  • Injections, Intraocular
  • Mitomycin (administration & dosage, therapeutic use)
  • Rabbits
  • Salivary Proteins and Peptides (administration & dosage, therapeutic use)
  • Thrombosis (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: